Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000743 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 | |
| SCHEMBL32664789 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 | |
| SCHEMBL30229527 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 | |
| Hydrochloric Acid SCHEMBL1998746 | 0.99 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 | |
| SCHEMBL25355634 | 0.91 | MDM4 (0.60) | MDM4TP53MDM2CASP3 | |
| SCHEMBL25357721 | 0.91 | MDM4 (0.60) | MDM4TP53MDM2CASP3 | |
| SCHEMBL25355639 | 0.91 | MDM4 (0.60) | MDM4TP53MDM2CASP3 | |
| SCHEMBL13863527 | 0.90 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 | |
| SCHEMBL1998935 | 0.90 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 | |
| SCHEMBL22444819 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7534763-B2 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | MDM4 4725/4885TP53 4340/4885MDM2 3332/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | MDM4 4869/4885TP53 4341/4885MDM2 3014/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | MDM4 4716/4885TP53 4593/4885MDM2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.